Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Invitae Corp (NVTA)

Invitae Corp (NVTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,393,301
  • Shares Outstanding, K 226,371
  • Annual Sales, $ 279,600 K
  • Annual Income, $ -602,170 K
  • 60-Month Beta 1.81
  • Price/Sales 12.76
  • Price/Cash Flow N/A
  • Price/Book 1.15
Trade NVTA with:

Options Overview Details

View History
  • Implied Volatility 90.55%
  • Historical Volatility 96.07%
  • IV Percentile 93%
  • IV Rank 62.58%
  • IV High 113.74% on 03/08/21
  • IV Low 51.77% on 09/02/21
  • Put/Call Vol Ratio 0.25
  • Today's Volume 2,954
  • Volume Avg (30-Day) 4,553
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 110,884
  • Open Int (30-Day) 111,505

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.72
  • Number of Estimates 6
  • High Estimate -0.62
  • Low Estimate -0.77
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.69 +2.03%
on 12/03/21
27.66 -45.81%
on 11/04/21
-12.37 (-45.21%)
since 11/03/21
3-Month
14.69 +2.03%
on 12/03/21
32.93 -54.48%
on 09/21/21
-16.25 (-52.02%)
since 09/03/21
52-Week
14.69 +2.03%
on 12/03/21
61.59 -75.66%
on 12/14/20
-35.08 (-70.06%)
since 12/03/20

Most Recent Stories

More News
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the...

EXAS : 76.59 (-4.94%)
DGX : 157.06 (+1.78%)
NVTA : 14.99 (-4.89%)
VCYT : 36.09 (-7.98%)
MYNZ : 8.12 (-8.14%)
Pre-Market Brief: S&P 500 Set to Open Slightly Higher on Benign U.S. PPI

Morning Markets Dec S&P 500 futures this morning are up +0.05%. Stock index futures are slightly higher this morning on relief that today’s U.S. producer price data for October came in near expectations....

RIOT : 28.64 (-13.13%)
MARA : 41.64 (-15.14%)
BTBT : 8.24 (-9.85%)
COIN : 265.65 (-6.69%)
FIVN : 128.60 (-5.98%)
EVGO : 11.18 (-5.17%)
RBLX : 113.79 (-2.68%)
REAL : 13.06 (-5.64%)
PYPL : 183.93 (-1.72%)
TRIP : 24.75 (-3.55%)
NVTA : 14.99 (-4.89%)
DDD : 21.23 (-3.85%)
Invitae (NVTA) Reports Q3 Loss, Lags Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of -17.39% and -8.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NVTA : 14.99 (-4.89%)
Invitae: Q3 Earnings Snapshot

SAN FRANCISCO (AP) _ Invitae Corp. (NVTA) on Monday reported a loss of $198.2 million in its third quarter.

NVTA : 14.99 (-4.89%)
Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NVTA : 14.99 (-4.89%)
Invitae to Announce Third Quarter 2021 Financial Results on Monday, November 8, 2021

/PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2021 financial...

NVTA : 14.99 (-4.89%)
Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress

/PRNewswire/ -- Invitae (NYSE: NVTA), University College London (UCL), and the Francis Crick Institute today announced new data from their TRACERx lung cancer...

NVTA : 14.99 (-4.89%)
Bull of the Day: Mesa Laboratories (MLAB)

Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division

MLAB : 310.12 (-0.46%)
DHR : 312.94 (-0.99%)
PACB : 20.47 (-5.06%)
NVTA : 14.99 (-4.89%)
NTRA : 86.56 (-5.69%)
Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director

CAMBRIDGE, United Kingdom, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Dante Labs , a global leader in genomics and precision medicine, today announced the appointments of Andre Nel, Dalila Rahmani, Laura...

ILMN : 347.28 (-2.85%)
NVTA : 14.99 (-4.89%)
Papyrus Therapeutics Inc. Announces Additions to Its Board of Directors

Papyrus Therapeutics Inc. is delighted to announce that two new members have joined our Board of Directors, Marc Beer as chairman and Professor James Lorens PhD as an independent director.

AEGR : 1.97 (+5.35%)
VIAC : 31.07 (+5.11%)
PKI : 183.17 (+1.77%)
ERYP : 2.49 (-1.97%)
NVTA : 14.99 (-4.89%)
NERV : 0.9262 (+1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 16.85
2nd Resistance Point 16.36
1st Resistance Point 15.68
Last Price 14.99
1st Support Level 14.50
2nd Support Level 14.01
3rd Support Level 13.32

See More

52-Week High 61.59
Fibonacci 61.8% 43.67
Fibonacci 50% 38.14
Fibonacci 38.2% 32.61
Last Price 14.99
52-Week Low 14.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar